#1 Clinical Trials Search in Europe

Daratumumab

Daratumumab, a monoclonal antibody targeting CD38, is being extensively studied in clinical trials for its efficacy and safety in treating multiple myeloma and other conditions. These trials aim to evaluate different dosing schedules, administration methods, and combinations with other therapies to optimize treatment outcomes for patients. The research spans various phases and includes healthy volunteers as well as patients with different stages of multiple myeloma.

Table of Contents

What is Daratumumab?

Daratumumab is a medication used to treat multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It is known by the brand name Darzalex[1]. Daratumumab is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein that targets specific cells in the body[2].

How Does Daratumumab Work?

Daratumumab works by targeting a protein called CD38, which is found on the surface of myeloma cells. When daratumumab attaches to CD38, it helps the immune system recognize and destroy the cancer cells[2]. This targeted approach allows daratumumab to attack cancer cells while potentially causing less damage to healthy cells compared to traditional chemotherapy.

What Conditions Does Daratumumab Treat?

Daratumumab is primarily used to treat multiple myeloma. It has shown effectiveness in treating:

  • Newly diagnosed multiple myeloma in patients who are not eligible for stem cell transplant[3]
  • Relapsed or refractory multiple myeloma (cancer that has returned after treatment or did not respond to initial treatment)[1]
Additionally, researchers are exploring its potential use in other conditions, such as:
  • Acute myeloblastic leukemia (AML) in older patients with poor prognosis[5]

How is Daratumumab Administered?

Daratumumab can be given in two ways:

  • Intravenous (IV) infusion: The medication is given directly into a vein. The dose is usually based on body weight, typically 16 mg/kg[2].
  • Subcutaneous injection: A newer form of daratumumab (called Darzalex Faspro) can be injected under the skin. This method uses a fixed dose of 1800 mg[3].
The frequency of administration depends on the specific treatment plan and may change over time. For example, it might be given weekly at first, then every two weeks, and later every four weeks[2].

Daratumumab in Combination Therapies

Daratumumab is often used in combination with other cancer treatments to enhance its effectiveness. Some combinations being studied include:

  • Daratumumab + Lenalidomide + Dexamethasone (DRd)[3]
  • Daratumumab + Bortezomib + Melphalan + Prednisone (D-VMP)[3]
  • Daratumumab + Pomalidomide + Dexamethasone[1]
These combination therapies aim to attack cancer cells through multiple mechanisms, potentially improving outcomes for patients.

Potential Side Effects

Like all medications, daratumumab can cause side effects. Common side effects may include:

  • Infusion-related reactions (such as fever, chills, or difficulty breathing)[4]
  • Fatigue
  • Nausea
  • Back pain
  • Cough
  • Upper respiratory tract infections
Your healthcare team will monitor you closely for these and other potential side effects. It’s important to report any new symptoms or concerns to your doctor promptly.

Ongoing Research

Researchers continue to study daratumumab to understand its full potential and optimize its use. Current areas of investigation include:

  • Comparing daratumumab to similar drugs (biosimilars) to potentially increase treatment options[4]
  • Testing daratumumab in combination with new drugs or treatment regimens[2]
  • Exploring its use in other types of cancer, such as acute myeloblastic leukemia[5]
  • Studying the long-term effects and outcomes of daratumumab treatment[3]
These ongoing studies aim to improve treatment options and outcomes for patients with multiple myeloma and potentially other cancers.

Aspect Details
Drug Name Daratumumab (DARZALEX®)
Primary Conditions Studied Multiple Myeloma, Smoldering Multiple Myeloma
Administration Methods Intravenous (IV) infusion, Subcutaneous injection
Dosing Schedules Various (weekly, bi-weekly, monthly, depending on study)
Key Objectives Pharmacokinetics, Safety, Tolerability, Immunogenicity, Efficacy
Study Populations Healthy volunteers, Multiple Myeloma patients (various stages)
Outcome Measures Response rates, Progression-free survival, Overall survival, Minimal residual disease
Comparative Studies Biosimilars, Different formulations, Home vs. Hospital administration
Safety Monitoring Adverse events, Laboratory tests, Vital signs, ECG

FAQ

  • What is Daratumumab? Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells. It is used in the treatment of multiple myeloma and is being studied for its potential in other conditions.
  • How is Daratumumab administered in clinical trials? In clinical trials, Daratumumab is administered in various ways, including intravenous (IV) infusion and subcutaneous injection. The dosing schedules vary depending on the study, ranging from weekly to monthly administrations.
  • What are the main objectives of Daratumumab clinical trials? The main objectives include evaluating the drug's pharmacokinetics, safety, tolerability, and immunogenicity. Some trials also aim to assess its efficacy in treating multiple myeloma, including response rates and progression-free survival.
  • Are there any studies comparing Daratumumab to other similar drugs? Yes, some trials compare Daratumumab (or its biosimilars) to other versions of the drug or to different treatment regimens. These studies help establish the comparability and potential advantages of different formulations or administration methods.
  • What types of patients are included in Daratumumab clinical trials? Daratumumab trials include a range of participants, from healthy volunteers to patients with various stages of multiple myeloma. Some studies focus on newly diagnosed patients, while others target those with relapsed or refractory disease.

Ongoing Clinical Trials on Daratumumab

  • Study of GEN3014 and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma and Other Blood Cancers

    Not recruiting

    1 1 1
    Investigated drugs:
    Czechia Denmark Greece Hungary Poland Spain +1

  • Study of Nivolumab, Ipilimumab, Relatlimab, and Daratumumab in Patients with Recurrent and Metastatic Colon Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy

  • Study on Daratumumab, Lenalidomide, and Dexamethasone for Patients with Primary Plasma Cell Leukemia

    Not recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Iberdomide and Dexamethasone, Alone or with Drug Combination, for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

    Not recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study of Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study of Daratumumab with Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Czechia Denmark France Germany Greece +5

  • Study of JNJ-68284528 for Treating Multiple Myeloma in Patients Using Ciltacabtagene Autoleucel and Drug Combination

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany The Netherlands Spain

  • Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Greece Italy +4

  • Study on the Effectiveness of Talquetamab and Teclistamab in First-Line Treatment for Transplant-Eligible Multiple Myeloma Patients

    Not recruiting

    1 1 1
    Investigated drugs:
    Denmark Estonia Norway

  • Study on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients

    Not recruiting

    1 1 1
    Investigated drugs:
    France

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Used in cancer treatment and diagnosis.
  • Multiple Myeloma: A type of blood cancer that affects plasma cells, a type of white blood cell that normally produces antibodies to fight infections.
  • Intravenous (IV) infusion: A method of administering medication directly into a vein using a needle or catheter.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Complete response (CR): The disappearance of all signs of cancer in response to treatment.
  • Minimal residual disease (MRD): A small number of cancer cells that remain in the body during or after treatment.
  • Adverse events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Biosimilar: A biological product that is highly similar to and has no clinically meaningful differences from an existing approved reference product.
  • Smoldering Multiple Myeloma: An early form of myeloma without symptoms that may progress to active multiple myeloma.
  • DARZALEX®: The brand name for Daratumumab, used in many clinical trials.
  • Anti-drug antibody (ADA): Antibodies produced by the immune system against a therapeutic drug, which can affect its efficacy and safety.

References